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Abstract
Background: The low carbohydrate, high fat ketogenic diet can be an effective anticonvulsant treatment in some
pediatric patients with pharmacoresistant epilepsy. Its mechanism(s) of action, however, remain uncertain. Direct
sampling of cerebrospinal fluid before and during metabolic therapy may reveal key changes associated with differential clinical outcomes. We characterized the relationship between seizure responsiveness and changes in lipid and
carbohydrate metabolites.
Methods: We performed metabolomic analysis of cerebrospinal fluid samples taken before and during ketogenic
diet treatment in patients with optimal response (100% seizure remission) and patients with no response (no seizure
improvement) to search for differential diet effects in hallmark metabolic compounds in these two groups. Optimal responders and non-responders were similar in age range and included males and females. Seizure types and
the etiologies or syndromes of epilepsy varied but did not appear to differ systematically between responders and
non-responders.
Results: Analysis showed a strong effect of ketogenic diet treatment on the cerebrospinal fluid metabolome. Longitudinal and between-subjects analyses revealed that many lipids and carbohydrates were changed significantly by
ketogenic diet, with changes typically being of larger magnitude in responders. Notably, responders had more robust
changes in glucose and the ketone bodies β-hydroxybutyrate and acetoacetate than non-responders; conversely,
non-responders had significant increases in fructose and sorbose, which did not occur in responders.
Conclusions: The data suggest that a differential and stronger metabolic response to the ketogenic diet may predict
a better anticonvulsant response, and such variability is likely due to inherent biological factors of individual patients.
Strategies to boost the metabolic response may be beneficial.
Keywords: Acetoacetate, Anticonvulsant, β-hydroxybutyrate, Cerebrospinal fluid, Glucose, Ketogenic diet, Pediatric
epilepsy
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Introduction
Epilepsy affects 1 in 26 people across the lifespan [1],
and 25–30% of patients suffer uncontrolled seizures
in spite of pharmacotherapy [2]. In addition, the incidence of side effects of anticonvulsants is high, and
can lead to cessation of medications [3, 4]. Ketogenic
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diet (KD) is a metabolic therapy that employs a highfat, low-carbohydrate, moderate-protein formulation
developed initially to mimic the metabolic state of
fasting [5, 6]: it is established as anticonvulsant [7],
antiepileptic [8], neuroprotective [9], and particularly
useful in some specific diagnoses [10] and in refractory epilepsy [11, 12].
Fasting and adhering to a KD each produce hallmark changes in blood ketone bodies (increased) and
glucose (decreased) but it has remained unclear how
these changes relate to beneficial effects. For instance,
blood ketone body levels do not always correlate with
anticonvulsant effects [13], and in general anticonvulsant benefits of ketones versus glucose in clinical and
laboratory work is mixed and still under active investigation and debate [14]. Furthermore, mechanistic links
between these metabolic blood chemistry changes
and anticonvulsant effects are unclear. Clearly many
systemic changes occur with dietary therapy, making
it difficult to sort out key mechanisms of efficacy. To
date a number of studies have examined changes in
blood metabolites aside from ketone bodies and glucose, typically examining a limited number of predetermined compounds to address specific hypotheses
[15–21]. While cerebrospinal fluid (CSF) is significantly more difficult to collect than blood, analysis of
CSF metabolites may be more relevant to KD mechanisms in epilepsy [22–25].
Metabolomics is a liquid chromatography/gas chromatography/mass spectroscopy-based technique for
quantifying all detectable small molecule metabolites,
such as carbohydrates, small lipids, amino acids, etc.
and has been used to describe biological phenotypes in
epilepsy [26] and other neurological disorders [27] as
well as dietary treatments [28]. Extant metabolomics
studies of serum and ketogenic diet have described
compensatory adaptations in amino acid metabolism
[29] and correlations between metabolites and fecal
microbiota [30] in experimental rodents. In general,
metabolomic analysis of CSF could be a powerful tool
for discovering KD-related mechanisms. Here we present novel data based on a set of CSF samples collected
twice from pediatric patients with refractory seizures
– once before KD treatment and once during KD treatment. This experimental design enables each patient to
serve as their own control, and thus the ability to compare baselines and changes in the metabolome to the
observed clinical response. A metabolomic analysis of
carbohydrates and lipids could relate the biochemical
effects of the KD to the magnitude of the clinical (anticonvulsant) response, and enables a review of predictors of KD efficacy.
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Methods
Ethics

The study was approved by the Ethics Committee of the
Karolinska Hospital and the informed consent of the parents and, when possible, patients, was obtained.
Patients

Patients have been described in detail previously [22, 23].
Briefly, the study was part of a larger prospective open
trial on the efficacy and safety of the KD in children with
epilepsy. The patients were enrolled consecutively as they
attended the Epilepsy Outpatient Clinic and the decision
to start the KD was made.
Inclusion criteria were an age of 1–18 years, pharmacologically refractory epilepsy with a prior trial of at least
three antiepileptic drugs, consideration of epilepsy surgery, no medical contraindications, family and patient
able to cooperate in a KD trial, and approval for performing two lumbar punctures before and during KD. Parents
and other caregivers made daily notes on the number and
type(s) of seizures on seizure calendars routinely used
in the clinic. Parental reports were compared with the
observations of seizure type and frequency made by the
epilepsy nurses during hospitalization. A subgroup of 27
children were selected based on the most differentiated
clinical outcome – namely those observed as seizurefree seizure and those with no observed improvement.
Five of the patients became seizure-free and were classified as having “optimal response” and five patients had
no detectable seizure reduction and were classified as
having “no response” (see Table 1). In these ten included
children metabolomics analysis with a focus on changes
in carbohydrates and lipids. These patients all had variable levels of intellectual disability except for one who had
autism spectrum disorder; patients were a mix of verbal
and non-verbal.
Study design

This pre-KD/during KD retrospective design, performed
between 1998 and 2002 at the Neuropediatric Department of the Astrid Lindgren Children’s Hospital, (Karolinska Hospital), has been described in detail previously
[22, 23]. To initiate the diet, patients were hospitalized
during a 4–5 day stay. The 1st CSF sampling was collected via lumbar puncture obtained immediately before
diet start and the 2nd CSF sampling was performed during a 2 day inpatient stay about 3 months after KD initiation when major fine-tuning adjustments of the diet
were made. During the 2nd sampling the patients were
on 3:1 or 4:1 KD ratio (Table 1). All lumbar punctures
were performed in the morning, around 8 AM, soon after
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Table 1 Patient demographics, sorted by clinical response
Characteristics of 5 patients with optimal seizure reduction (no detected seizures)
sex

age

Epilepsy type(s) Seizure type(s)

Etiology/syndrome

AEDs

Diet ratio

M

4.5

generalized

Doose syndrome

VPA, CZP

4:1

Myoclonic, generalized T/C

F

4.8

generalized

Myoclonic, tonic, absence

L-G syndrome

CLB

3:1

M

5.1

generalized

Myoclonic, tonic

Down’s syndrome

VPA, LTG

4:1

F

5.8

generalized

Myoclonic, generalized T/C

Cortical dysplasia (polymicrogyria)

none

3:1

F

9.0

focal

Focal without impaired awareness

Cortical dysplasia

PRI, VPA

4:1

Mean: 5.8
Characteristics of 5 patients with no observed change in seizures
M

4.0

generalized

Myoclonic, tonic, epileptic spasms

Inverted duplicated chromosome 15, L-G syndrome LTG, TPM

4:1

M

6.0

generalized

Epileptic spasms, generalized T/C

L-G syndrome

VPA, LTG

3:1
4:1

M

6.3

generalized

Myoclonic, absence, generalized T/C Infantile spasms, L-G syndrome

VPA, CLB

F

6.7

generalized

Generalized T/C

Unknown

LTG, PB, TPM 4:1

M

10.1 generalized

Myoclonic, atonic

Agenesi corpus callosum, other CNS malformations

VPA, CZP

4:1

Mean: 6.6
Seizure types classified according to the International League Against Epilepsy (ILAE) classification [31]. “Diet ratio” indicates the (fat:(protein + carbohydrate)) ratio of
the KD at time of 2nd lumbar puncture. Abbreviations: AED antiepileptic drug, T/C tonic/clonic, L-G Lennox-Gastaux syndrome, VPA valproic acid, CZP clonazepam, CLB
clobazam, LTG lamotrigine, PRI primidone, TPM topiramate, PB phenobarbital

breakfast. During both lumbar punctures, four mL CSF
was collected: samples with visible blood content were
not used. Aliquots were immediately cold-centrifuged,
supernatant collected, frozen, and stored at − 70 °C. Prior
studies have shown that metabolites stored at this temperature are expected to remain stable for decades [32,
33]. Serum β-hydroxybutyrate (β-HB) levels were measured the same morning before breakfast of the 2nd lumbar puncture and analyzed consecutively.
The diet followed a standardized protocol for the classic KD, which is a slightly modified version of the protocol of the Johns Hopkins Hospital [34]. Most patients
were started at a 4:1 (fats:(proteins + carbohydrates))
ratio. A minimum of 1 g/kg body weight per day of protein was used. At diet start supplements of vitamins and
minerals were given to all patients as well as carnitine
(100 mg/kg body weight per day). All calculations of the
amount of calories and the nutrient composition of the
menus of the diet were made for the individual child by a
specially trained dietician.
The parents were educated on all aspects of the diet
by a specialized dietician, neuropediatrician, and keto
nurse during a 4–5 days inpatient stay at diet start. The
parents were carefully instructed on the importance of
being accurate in preparing the menus of the diet, and on
keeping detailed diaries. Dietary compliance was monitored by daily testing of urine ketones at home by parents
with data reported to nurses, and also by blood testing
for β-hydroxybutyrate during frequent visits with the diet
team consisting of nurse, dietician and neuropediatrician.
Members of the team had frequent (sometimes daily) telephone consultations with parents on how to manage the

diet. Also, diaries were discussed with the team during
clinic visits at 1 and 3 months of treatment. Medications
were not changed during the study, with the exception of
slight decreases in some children.
Metabolomics

Frozen CSF samples (20 total) were sent to Metabolon
(Durham, North Carolina) for metabolomics analysis
in 2014. Samples were prepared and extracted. Internal standards were added to every analyzed sample as
an internal quality control; samples were split into fractions for ultra-high performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) with
positive ionization, UPLC-MS/MS with negative ionization, and gas chromatography–mass spectrometry
(GC-MS). The UPLC-MS/MS platform utilizes Waters
Acquity UPLC with Waters UPLC BEH C18 or BEH
Amide 2.1 × 100 mm, 1.7 μm columns and a ThermoScientific Q-Exactive high resolution/accurate mass spectrometer interfaced with a heated electrospray ionization
(HESI-II) source and Orbitrap mass analyzer operated at
35,000 mass resolution. The GC-MS platform utilizes a
Thermo-Finnigan Trace DSQ fast-scanning single-quadrupole MS using electron impact ionization operated at
unit mass resolving power (scan range 50–750 m/z), with
a 5% diphenyl/95% dimethyl polysiloxane fused silica column (20 m × 0.18 mm ID; 0.18 um film thickness) with
helium as carrier gas and a temperature ramp from 60°
to 340 °C in a 17.5 min period. Metabolites were identified by automated comparison of the ion features in the
experimental samples to a reference library of chemical
standard entries that include retention time, molecular

Masino et al. Nutr Metab (Lond)

(2021) 18:23

weight (m/z), preferred adducts, and in-source fragments as well as associated MS spectra. Identification
of known chemical entities was based on comparison to
metabolomic library entries of ~ 4500 purified standards.
Raw data (ion counts) for each metabolite were scaled
so that the median equaled one; missing values (nondetections) were imputed with half the minimum value.
Statistical analysis (performed by Metabolon) included
ANOVA, and paired and unpaired t-tests as appropriate.
False discovery rate (q) was calculated for multiple comparisons: here we consider q < 0.10 to indicate high confidence in a result, and 0.10 < q < 0.20 to indicate moderate
confidence.

Results
The patient group included all five children with 100%
seizure reduction (“optimal response”) and all five
patients with no seizure reduction; demographics of the
patient group are given in Table 1. Patients with optimal
seizure response and no observed seizure remission to
KD treatment had similar age ranges and included both
males and females. Seizure types and the etiology of the
epilepsy or epilepsy syndrome varied and did not appear
to differ systematically between patients with an optimal
vs. no observable clinical response. Similarly, anticonvulsant drug treatment did not appear to differ systematically between the two groups, nor did KD ratio. Statistical
analysis was not performed on these factors due to variability, overlap in diagnostic categories and small sample
size.
In CSF samples from these patients, 271 metabolites
were identified. We focused on analyzing CSF compounds in the lipid and carbohydrate families (49 and
25 compounds detected, respectively. In the lipid family 25/49 compounds changed significantly (comparing
baseline to during KD) in patients with an optimal vs. no
observable clinical response; in the carbohydrate family,
15/25 changed significantly in optimal or no observable
clinical response (Table 2). Considering both families
together, there was a strong trend (p = 0.066) for more
compounds to change baseline-to-KD in patients with an
optimal vs. no observable clinical response.
CSF lipids and their metabolites were mostly
increased by KD treatment (Table 2), including the
hydroxylated derivatives and carnitine esters of
medium- and short-chain fatty acids. The ketone bodies acetoacetate and β-hydroxybutyrate were increased
many-fold, and although the ketone body acetone
was not itself detected, its metabolite 1,2-propanediol [35] was detected and elevated significantly.
There were large increases in trimethylamine N-oxide
(a gut microbiotic metabolite of dietary carnitine and
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lecithin) and glycocholate (a gut microbiota-modified
bile acid). There were decreases in methylmalonylcarnitine (involved in fatty acid synthesis) and glycerol
3-phosphate (a triglyceride metabolite). Many of these
changes were significant only in optimal responders.
Regarding compounds that were significantly changed
in both patients with an optimal vs. no observable
clinical response (e.g. hexanoyl- and acetyl-carnitine,
3-hydroxyoctanoate, trimethylamine N-oxide), examination of the fold changes in means reveals larger magnitude changes in optimal responders.
Not surprisingly, since a KD greatly reduces dietary
carbohydrates, CSF sugars and their metabolites/derivatives during KD therapy changed greatly from baseline to during KD (Table 3). Some carbohydrates were
decreased, including glucose (significant only in optimal
responders) and the glycemic indicator 1,5-anhydroglucitol [36]. A number of hexoses and pentoses, however,
were increased. Elevated pyruvate in brain was previously noted in rodents eating a KD [37]. Notably, sorbose
and fructose were significantly increased only in patients
with no clinical response.
As for between-subjects comparisons of CSF metabolites in patients with an optimal vs. no clinical response
during KD treatment, no compounds survived application of a false-discovery rate correction. However, several
showed differences that were significant with uncorrected t-tests (Table 4), and these demonstrated a pattern
that supported the within-subjects comparison. Ketone
bodies and some fatty acids and hydroxylated fatty acids
were several-fold higher in patients with optimal vs. no
clinical response. In addition, glucose, sorbose, and fructose were lower in optimal responders.
Between-subject comparisons of CSF metabolites in
patients with optimal vs. no clinical response in baseline samples revealed only one compound that was significant with an uncorrected t-test at p < 0.05: the hexose
mannose, higher in patients with no clinical response
(Table 4).
Statistical analysis was further focused on the hallmark changes in biochemistry within the lipid and
carbohydrate families, namely the ketone bodies and
glucose. We applied two-by-two ANOVAs to these
CSF metabolites with clinical response to KD and
time as factors. There were no baseline differences
between the groups (locants are overlapping in Fig. 1).
As expected, ketone bodies (β-hydroxybutyrate and
acetoacetate) were elevated and glucose was lowered
during KD treatment; however, all these responses
were significantly smaller in the patients with no clinical response vs. those with optimal response (Fig. 1).
Serum levels of β-hydroxybutyrate during KD were also
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Table 2 Ketogenic diet-induced changes in lipids
During diet/Prediet
Compound Family

Compound

optimal response

no response

Ketone Bodies

1,2-propanediol

29.16***

7.47**

Acyl Carnitines

Carnitine Metabolism

Monohydroxy Fatty Acids

Medium Chain Fatty Acids

Phospholipid Metabolism

Amide Fatty Acid
Dicarboxylate Fatty Acids
Triglyceride Metabolism
Lysophospholipids

Inositol Metabolism
Amino Fatty Acids

Acetoacetate

130.8***

67.5***

β-hydroxybutyrate

175.5***

57.4***

Propionyl-carnitine

1.50*

1.48

Acetyl-carnitine

5.19***

3.89*

Butyryl-carnitine

5.51**

2.40

Octanoyl-carnitine

9.43***

5.44

Hexanoyl-carnitine

16.09***

4.73**

3-hydroxybutyryl-carnitine

23.63***

15.84**

Carnitine

0.99

1.19

Deoxycarnitine

2.00

1.35

3-dehydrocarnitine

61.96***

108.5***

2-hydroxyhexanoate

1.28

2.10

3-hydroxypropanoate

2.35

1.46

γ-hydroxybutyrate

3.40***

2.06**

5-hydroxyhexanoate

6.48*

2.29*

3-hydroxyoctanoate

10.35***

3.48***

3-hydroxysebacate

22.12**

6.70

Nonanoic acid

0.97

1.19

Dodecanoic acid

1.05

0.98

Decanoic acid

1.14*

1.12

Octanoic acid

1.90

1.15

Heptanoic acid

2.24

0.73

Hexanoic acid

3.29

1.49

Choline

0.96

0.94

Phosphoethanolamine

1.02

1.26

Choline phosphate

1.47

2.50

Trimethylamine N-oxide

715.1**

375.3**

Oleamide

0.99

16.48

2-hydroxyglutarate

2.05

1.07

CMPF

8.81*

2.61

Glycerol 3-phosphate

0.82**

0.86

Glycerol

1.22

0.89

1-oleoyl-GPC (18:1)

0.46*

2.27

1-docosahexaenoyl-GPE (22:6)

0.93

0.84

1-oleoyl-GPE (18:1)

1.29

1.51

1-palmitoyl-GPC (16:0)

3.16

1.90

Scyllo-inositol

0.84

0.81

Myo-inositol

1.12

0.81

2-aminoheptanoate

1.38

1.67

2-aminooctanoate

631.4

9.24*

Fatty Acid Synthesis

2-methylmalonylcarnitine

0.64***

0.69*

Polyunsaturated Fatty Acid

Docosahexaenoate (22:6n3)

2.05

1.07

Primary Bile Acid Metabolism

Glycocholate

12.08*

2.44

Sphingolipid Metabolism

Palmitoyl sphingomyelin (d18:1/16:0)

2.66*

1.73

Corticosteroids

Cortisone

0.73**

1.19

Cortisol

0.98

1.65

Androgenic Steroid

Androstenediol (3β,17β) disulfate

6.31

6.02

Sterols

7-α-HOCA

0.95

0.88*

Ratios are fold changes from during KD compared to before KD. Compounds are grouped by compound family, and by optimal response ratio within that family.
Significant increases are indicated with bold, significant decreases with italics. False-discovery rates: *0.10 < q < 0.20, **0.05 < q < 0.10, ***q < 0.05. 7-HOCA – 7-alphahydroxy-3-oxo-4-cholestenoate, CMPF – 3-carboxy-4-methyl-5-propyl-2-furanpropanoate, GPC glycerol-3-phosphocholine, GPE glycero-3-phosphoethanolamine
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Table 3 Diet-induced changes in carbohydrates
During diet/Prediet
Compound Family

Compound

optimal response

no response

Glycolysis

1,5-anhydroglucitol

0.57**

0.47**

Hexose Metabolism

Pentose Metabolism

Aminosugar Metabolism

Advanced Glycation End-product

Glucose

0.83***

0.93

Lactate

0.96

1.05

Glycerate

1.12

0.99

Pyruvate

1.18***

1.93

Galactitol (dulcitol)

0.67**

0.87

Sorbose

0.71*

8.04**

Sorbitol

1.11

1.27

Fructose

1.13

1.46**

Mannose

1.52***

1.35***

Mannitol

1.66***

1.70**

Threitol

0.61*

0.74*

Xylitol

0.94

0.92

Ribitol

1.04

0.97

Xylose

1.12

1.04

Ribose

1.18

1.12

Ribulose

1.37*

1.16

Xylonate

1.38**

1.15

Arabitol

1.54***

1.48**

Arabinose

2.38***

1.63***

Erythronate

0.84*

0.77**

N-acetylneuraminate

0.98

0.93

Glucuronate

1.04

1.04

Erythrulose

1.3

0.58*

Ratios are fold changes from during KD compared to before KD. Compounds are grouped by compound family, and by optimal response ratio within that family.
Significant increases are indicated with bold, significant decreases with italics. False-discovery rates: *0.10 < q < 0.20, **0.05 < q < 0.10, ***q < 0.05

significantly lower in patients with no clinical response
(3.2 ± 0.4 mM) vs. those with optimal response
(5.2 ± 0.1 mM, p < 0.01), expected as CSF ketone body
levels track blood levels [38–42].
Follow-up data are available on all patients. In the 5
patients who rapidly acquired seizure freedom, “optimal responders”, the KD was continued between 2 years
and 4.6 years. In three of these the KD was tapered and
several years after discontinuation of the diet they were
still seizure-free. In two patients, however, seizures
came back during tapering: in one there are very few
seizures but in the other the seizures were as bad as
before KD. In the five patients with no seizure response,
the diet was tapered after 3–4 months in three patients,
but parents of two patients persevered with the KD
because of improved communication and better alertness. Dietary treatment was continued for 2–3 years
with these behavioral improvements persisting.

Discussion
We characterized KD-induced changes in the CSF lipid/
carbohydrate metabolome in pediatric epilepsy patients
with the most distinct clinical behavioral responses
at 3 months: either no detectable seizures (optimal
response) or no detectable change in the frequency of
refractory seizures. A major finding from this analysis,
supported by longitudinal and between-subjects analyses, is that those patients who had an optimal response
had a stronger metabolic response to the KD than those
patients who showed no seizure improvement. This
effect was evident by a larger number of KD-changed
compounds and a larger magnitude change in most of
those compounds in optimal responders – including glucose and the ketone bodies. While this pattern might be
interpreted to indicate that the patients with no clinical
response were less compliant, there is some evidence to
suggest this is not true. For example, diet compliance was
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Table 4 Between-subject differences, optimal v. no response, on and before ketogenic diet
During KD

responders / non-responders

Compound family

Compound

Ketone Bodies

β-hydroxybutyrate

3.24**

acetoacetate

3.88**

1,2-propanediol

4.74*

Monohydroxy Fatty Acids

γ-hydroxybutyrate

2.06**

3-hydroxyoctanoate

2.61**

Medium Chain Fatty Acid

hexanoic acid

2.79**

Triglyceride Metabolism

glycerol

1.34*

Glycolysis

glycerate

0.62*

glucose

0.88**

Hexoses

sorbose

0.28**

fructose

0.75**

Baseline
Acyl Carnitines
Corticosteroids

acetylcarnitine

0.72*

cortisol

1.36*

Hexoses

mannose

0.72**

Tetroses

erythrulose

0.34*

Ratios are fold difference between patients with an optimal vs. no clinical response. Only compounds with p < 0.10 are listed. *0.05 < p < 0.10, **p < 0.05

Fig. 1 Hallmark changes in ketone bodies β-hydroxybutyrate (left) and acetoacetate (middle) and glucose (right) are greater in CSF from patients
with optimal response compared to those with no response. Data are scaled to one (indicated by dashed lines); means and standard errors are
shown. See text for quantified β-hydroxybutyrate level. ANOVA group-x-time interactions: β-hydroxybutyrate F = 6.8, p = 0.031; acetoacetate
F = 11.6, p = 0.009; glucose F = 5.8, p = 0.043. There were also significant main effects of time and patient group for each metabolite. ** p < 0.01, ***
p < 0.001 compared to pre-KD; †p < 0.05, ††p < 0.01, †††p < 0.001 compared to optimal responder during KD

described as good by caretakers and medical personnel.
Furthermore, all patients with no clinical response (as
well those with optimal response) had striking elevations
of CSF ketone bodies during KD compared to pre-diet
(and high blood ketone bodies during KD), confirming
adherence to a KD that precipitated a shift to ketonebased metabolism. Thus, these differences may be due

to inherent biological variability in metabolic response.
We cannot rule out, however, that some external dietary
factors (exact ratio of KD administered, types of fat or of
protein, etc.) could be involved.
Of paramount interest is the identification of compounds that could be mechanistically involved in the
anticonvulsant effect of a robust metabolic response. The
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eponymous products of a KD are an obvious candidate
[14]. Beyond being a more efficient fuel for in oxidative metabolism and mitochondrial health, ketone bodies are putative signaling molecules in several pathways
that should improve the state of hyperexcitable brain
tissue, including inhibitory ion channels [43], vesicular
glutamate release [44], inflammation [45], nicotinamide
adenine dinucleotide oxidation state [46], and histone
deacetylases [47]. It was realized in the earliest KD studies that some threshold level of blood ketone bodies
needed to be reached for beneficial outcomes [48, 49].
Beyond that, however, the connection of elevated blood
ketone bodies and anticonvulsant effects clinically has
been controversial, described as correlated [50–52] or
not [53]. Studies have noted that some individual patients
benefit despite not being in ketosis [54–56] or have
described a correlation only at certain lengths of KD
treatment [55, 57].
Besides elevating brain ketone body levels via the liver,
low glucose appears to have direct effects in brain. Mildly
lowered glucose promotes an autocrine inhibition in
pyramidal neurons in vitro based on the neuromodulator
adenosine [58]. This same mechanism is invoked by KD
treatment [59] and is anti-seizure [60]. Similarly, partial
block of glycolysis with 2-deoxyglucose tempers epileptiform activity in vitro [61] and seizures in vivo in some
models [62]. Low glycemic index diets can be anticonvulsant in the absence of ketosis [63, 64], and low glucose
rather than elevated ketone bodies seems to underlie the
anticonvulsant action of caloric restriction [65]. At the
other end of the glycolytic pathway, elevated pyruvate
was significant in optimal responders only, which may
indicate decreased usage due to increased acetyl-CoA
production from ketone bodies.
Acetyl-carnitine, associated with dietary red meat [28]
is involved in synthesis of acetyl-CoA. Although little
work has been done with seizures directly [66], this molecule is thought to be neuroprotective, neurotrophic, and
antioxidant. Notably, acetyl-carnitine is well-tolerated as
a dietary supplement [67].
Conversely, this metabolomics analysis revealed some
elevated compounds that may be mechanistically detrimental to the efficacy of a KD. KD-related elevations in
fructose and sorbose occur in patients with no clinical
response and not those with optimal response. Because
fructose and sorbose can be metabolized to fructose6-phosphate, these KD-related changes could augment
glycolytic metabolites downstream of glucose. Combined
with a smaller reduction in glucose itself in patients with
no clinical response, this pattern might indicate that
substantial amounts of acetyl-coA are still entering the
Kreb’s cycle from the glycolytic pathway. This state may
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offset the enhanced efficiency of adenosine triphosphate
production during ketolysis, undermining the beneficial
effects of the KD-related metabolic state presumably
occurring with full force in optimal responders.
Many detected compounds likely reflect a stronger
metabolic response to the KD in optimal responders
without being mechanistically involved in a better anticonvulsant response. For instance, increases in trimethylamine N-oxide is to be expected in a diet rich in meat,
fish, and eggs; changes in glycocholate and methylmalonyl carnitine comport with a high fat diet; decreased
glycerol 3-phosphate could be due to increased shunting into glycolysis (via dihydroxyacetone phosphate) to
augment this underpowered pathway – none of these
metabolites are thought to have signaling properties in
brain. 3-hydroxyoctanoate is a signaling molecule with
specific receptors expressed in adipocytes but not brain
[68]. γ-hydroxybutyrate also acts on specific receptors
(GPR172A), and is used exogenously as an abused hypnotic/sedative drug. However, antagonism of GPR172A is
anticonvulsant; conversely, activation is used to produce
an animal model of absence seizures [69] making higher
γ-hydroxybutyrate unlikely to be involved in a better
anticonvulsant response to the KD. It was hypothesized
that elevated β-hydroxybutyrate might mediate the mild
euphoria found during fasting and sometimes during KD
[70] by acting pharmacologically like γ-hydroxybutyrate;
however, elevated γ-hydroxybutyrate itself may underlie
this effect.
These findings can be related to prior clinical studies of the plasma metabolome, and some changes found
in plasma were not present in these CSF samples. For
instance, KD did not elevate cortisol in CSF, whereas it
has been reported to do so in plasma; these latter studies were, however, in rheumatoid arthritis patients [19,
53]. Cappuccio et al. reported elevated plasma hydroxybutyryl- and acetyl-carnitine and lower methylmalonylcarnitine in KD-treated glucose transporter 1 deficient
patients [16], similar to the present results. Also, Schoeler et al. demonstrated a stronger β-hydroxybutyrate
response to KD treatment in patients with optimal clinical response vs. those with no response; however, they
also reported that optimal responders had higher baseline CSF β-hydroxybutyrate and octanoyl- and acetylcarnitine [21]. We did not replicate those findings, and
in fact showed a trend for lower initial acetyl-carnitine
in optimal responders (and a significant increase during
KD was also specific to optimal responders – showing
a strong regulation by KD). These discrepancies could
be due to true differences between plasma and CSF, or
might reflect dissimilar definitions of patients with optimal response or no clinical response.
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We acknowledge some limitations to the present study.
The number of subjects is low, which reduces statistical
power. Also, we are unaware of any clinical study that
describes effects of the presently-used anticonvulsants
on CSF levels of our metabolites of interest, so if and
how these drugs had any effect remains unknown. Last,
metabolomics was not performed on plasma, which
was collected but lost in a freezer accident. This could
have indicated correlations between CSF and plasma
and possibly identified blood-born predictors of clinical
response.
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Conclusions
In a small but valuable clinical cohort with pre- and
post-KD CSF sampling, we found a more effective anticonvulsant response correlated with a stronger central metabolic response at 3 months of KD treatment.
Such samples present a special opportunity as studies
with sequential lumbar punctures in pediatric patients
are rare, but allow for within-subjects analysis. This
study extends and complements prior work on monoamine and amino acid neurotransmitters in CSF [22,
23]. Focused studies of specific metabolites are valuable, but the unpredicted changes found here (such as
KD-elevated levels of hexoses only in non-reponders)
highlight the importance of casting a wide net. Further
work is needed and could determine more quantitatively if a strong central metabolic response early in KD
treatment predicts an ultimately effective anticonvulsant outcome, information that may be useful in decisions about treatment adjuvants, adjustments and/or
continuation. In addition, a blood-based correlate that
predicts efficacy would be extremely valuable because
CSF collection is necessarily invasive. It is worth noting
that some of the relevant metabolites (ketone bodies,
1,2-propanediol, glycerol 3-phosphate) are detectable
with 1H or 31P nuclear magnetic resonance spectroscopy. For those whose poor anticonvulsant response
may due to inherent biological factors, on possibility is
that KD treatment could be amplified by manipulating
hallmark metabolic changes directly – for example supplementing with relevant molecules, e.g. ketone bodies
(via precursors such as ketone esters, medium chain
triglycerides, or coconut oil) or acetyl-carnitine.
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